Fennec Pharmaceuticals (FENC) Revenue & Revenue Breakdown
Fennec Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$21.64M
Latest Revenue (Q)
$6.97M
Main Segment (Y)
Royalty
Fennec Pharmaceuticals Revenue by Period
Fennec Pharmaceuticals Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | $21.64M | 1309.89% |
2022-12-31 | $1.53M | 100.00% |
2021-12-31 | - | -100.00% |
2020-12-31 | $170.00K | 100.00% |
2019-12-31 | - | 100.00% |
2018-12-31 | - | 100.00% |
2017-12-31 | - | 100.00% |
2016-12-31 | - | 100.00% |
2015-12-31 | - | 100.00% |
2014-12-31 | - | 100.00% |
2013-12-31 | - | 100.00% |
2012-12-31 | - | 100.00% |
2011-12-31 | - | 100.00% |
2010-12-31 | - | 100.00% |
2009-12-31 | - | 100.00% |
2008-12-31 | - | 100.00% |
2007-12-31 | - | 100.00% |
2006-12-31 | - | 100.00% |
2005-12-31 | - | 100.00% |
2004-06-30 | - | 100.00% |
2003-06-30 | - | 100.00% |
2002-06-30 | - | -100.00% |
2001-06-30 | $0.66 | -2.94% |
2000-06-30 | $0.68 | - |
Fennec Pharmaceuticals Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-09-30 | $6.97M | -3.95% |
2024-06-30 | $7.26M | -71.26% |
2024-03-31 | $25.26M | 152.53% |
2023-12-31 | $10.00M | 53.55% |
2023-09-30 | $6.51M | 95.94% |
2023-06-30 | $3.33M | 98.27% |
2023-03-31 | $1.68M | 9.25% |
2022-12-31 | $1.53M | 100.00% |
2022-09-30 | - | 100.00% |
2022-06-30 | - | 100.00% |
2022-03-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2021-09-30 | - | 100.00% |
2021-06-30 | - | 100.00% |
2021-03-31 | - | -100.00% |
2020-12-31 | $170.00K | 100.00% |
2020-09-30 | - | 100.00% |
2020-06-30 | - | 100.00% |
2020-03-31 | - | 100.00% |
2019-12-31 | - | 100.00% |
2019-09-30 | - | 100.00% |
2019-06-30 | - | 100.00% |
2019-03-31 | - | 100.00% |
2018-12-31 | - | 100.00% |
2018-09-30 | - | 100.00% |
2018-06-30 | - | 100.00% |
2018-03-31 | - | 100.00% |
2017-12-31 | - | 100.00% |
2017-09-30 | - | 100.00% |
2017-06-30 | - | 100.00% |
2017-03-31 | - | 100.00% |
2016-12-31 | - | 100.00% |
2016-09-30 | - | 100.00% |
2016-06-30 | - | 100.00% |
2016-03-31 | - | 100.00% |
2015-12-31 | - | 100.00% |
2015-09-30 | - | 100.00% |
2015-06-30 | - | 100.00% |
2015-03-31 | - | 100.00% |
2014-12-31 | - | 100.00% |
2014-09-30 | - | 100.00% |
2014-06-30 | - | 100.00% |
2014-03-31 | - | 100.00% |
2013-12-31 | - | 100.00% |
2013-09-30 | - | 100.00% |
2013-06-30 | - | 100.00% |
2013-03-31 | - | 100.00% |
2012-12-31 | - | 100.00% |
2012-09-30 | - | 100.00% |
2012-06-30 | - | 100.00% |
2012-03-31 | - | 100.00% |
2011-12-31 | - | 100.00% |
2011-09-30 | - | 100.00% |
2011-06-30 | - | 100.00% |
2011-03-31 | - | 100.00% |
2010-12-31 | - | 100.00% |
2010-09-30 | - | 100.00% |
2010-06-30 | - | 100.00% |
2010-03-31 | - | 100.00% |
2009-12-31 | - | 100.00% |
2009-09-30 | - | 100.00% |
2009-06-30 | - | 100.00% |
2009-03-31 | - | 100.00% |
2008-12-31 | - | 100.00% |
2008-09-30 | - | 100.00% |
2008-06-30 | - | 100.00% |
2008-03-31 | - | 100.00% |
2007-12-31 | - | - |
Fennec Pharmaceuticals Revenue Breakdown
Fennec Pharmaceuticals Revenue Breakdown by Product
Annual Revenue by Product
Product/Service | Dec 20 |
---|---|
Royalty | $170.00K |
Latest
Fennec Pharmaceuticals Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
HRMY | Harmony Biosciences | $582.02M | $186.04M |
FENC | Fennec Pharmaceuticals | $21.64M | $6.97M |
IKNA | Ikena Oncology | $9.16M | - |
JANX | Janux Therapeutics | $8.08M | $8.90M |
MOLN | Molecular Partners | $7.04M | $2.74M |
OBIO | Orchestra BioMed | $2.76M | $778.00K |
MNOV | MediciNova | $1.00M | - |
KROS | Keros Therapeutics | $151.00K | $37.00K |
ANEB | Anebulo Pharmaceuticals | - | - |
AVTE | Aerovate Therapeutics | - | - |
IRON | Disc Medicine | - | - |
OLMA | Olema Pharmaceuticals | - | - |
LRMR | Larimar Therapeutics | - | - |
EWTX | Edgewise Therapeutics | - | - |
CSBR | Champions Oncology | - | $-14.06M |